IRULYA THERAPEUTICS INC
About IRULYA THERAPEUTICS INC
IRulya Therapeutics Inc. is a biotechnology company focused on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. Its lead asset candidate, eDSP, is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases including A-T, an inherited autosomal recessive disorder caused by mutations in the ATM gene. The company’s AIDE technology platform is a drug/device combination that uses an automated process to encapsulate a drug into a patient’s own red blood cells.
- 🔗 About IRulya Therapeutics Inc (IRLA) - Investing.com
- 🔗 IRulya Share Price Today | NASDAQ: IRLA - Investing.com IN
- 🔗 IRulya Therapeutics Inc Stock Price Today | NASDAQ: IRLA Live - Investing.com
- 🔗 IRulya Share Price Today | NASDAQ IRLA Stock - Investing.com AU
- 🔗 IRulya Therapeutics Inc. Common Stock (IRLA) News Headlines | Nasdaq
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Lead candidate eDSP is in Phase 3 for A-T and other rare pediatric neurodegenerative diseases.
- AIDE technology platform encapsulates drugs into autologous red blood cells via automated equipment.
- Employs 38 people and is headquartered in New Haven, CT.
- NASDAQ-listed (IRLA) with $33.6M market capitalization.
Ask StreetZero about IRULYA THERAPEUTICS INC
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account